You have requested access to member-only content.
Digging into 2018 OPPS financials beyond 340B reductions
CMS’ policy in the 2018 OPPS final rule to cut reimbursement for drugs purchased through the 340B drug discount program by nearly 30%, accounting for the decrease from average sales price plus 6% to minus 22.5%, is getting a lot of attention from the provider community—and with good reason.
This is an excerpt from member-only content. Please log in or become a member.
Log in to access this content:
Unable to log in?
Click here to reset your password or unlock your account.
Forgot your username?
Contact customer care at customerservice@hcpro.com or call 800-650-6787, between 8 AM - 5 PM CT
Not a member? Join now!
Revenue Cycle Advisor is the key to your organization's Medicare regulatory news and education. It combines all of HCPro's Medicare regulatory and reimbursement resources into one handy and easy-to-access portal. News is not just repeated from other sources. It is analyzed by our Medicare experts so professionals can comprehend any new rule updates thoroughly.
For questions and support, please call customer service: 800-650-6787.
Try before you buy with our FREE samples!